Development and validation of models predicting treatment patterns in women with urinary urgency and/or urgency incontinence: A Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study.

PURPOSE To develop a tool to predict a woman's treatment pattern for bothersome urinary urgency (UU) and/or UU incontinence over 1 year after presenting for care at urology or urogynecology clinics. METHODS The Symptoms of Lower Urinary Tract Dysfunction Research Network observational cohort study enrolled adult women with bothersome UU and/or UU incontinence using the lower urinary tract symptoms (LUTS) Tool who were seeking care for LUTS. Treatments for UU and/or urgency incontinence were ordered from least to most invasive. Ordinal logistic and Cox proportional hazard regression models were fit to predict the most invasive level of treatment during follow-up and overactive bladder (OAB) medication discontinuation, respectively. Binary logistic regression was performed to predict sling treatment during the study follow-up. Clinical tools were then created using the models listed above to predict treatment pattern over 12 months. RESULTS Among 349 women, 281 reported UU incontinence, and 68 reported UU at baseline. The highest level of treatment during the study was as follows: 20% no treatment, 24% behavioral treatments, 23% physical therapy, 26% OAB medication, 1% percutaneous tibial nerve stimulation, 3% onabotulinumtoxin A, and 3% sacral neuromodulation. Slings were placed in 10% (n = 36) of participants before baseline and in 11% (n = 40) during study follow-up. Baseline factors associated with predicting the most invasive level of treatment included baseline level of treatment, hypertension, UU incontinence severity, stress urinary incontinence (SUI) severity, and anticholinergic burden score. Less severe baseline depression and less severe UU incontinence were associated with OAB medication discontinuation. UU and SUI severity were associated with sling placement during the study period. Three tools are available to predict: (1) highest level of treatment; (2) OAB medication discontinuation; and (3) sling placement. CONCLUSIONS OAB treatment prediction tools developed in this study can help providers individualize treatment plans and identify not only patients at risk for treatment discontinuation but also patients who may not be escalated to potentially beneficial OAB treatments, with the goal to improve clinical outcomes for patients suffering from this chronic and often debilitating condition.

[1]  R. Dmochowski,et al.  Associations Between Unmet Social Needs and Overactive Bladder , 2022, The Journal of urology.

[2]  William T. Berg,et al.  A retrospective longitudinal evaluation of new overactive bladder patients in an FPMRS urologist practice: Are patients following up and utilizing third‐line therapies? , 2020, Neurourology and urodynamics.

[3]  T. Soda,et al.  Overactive bladder medication: Persistence, drug switching, and reinitiation , 2020, Neurourology and urodynamics.

[4]  E. Illiano,et al.  Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder , 2020, International Urology and Nephrology.

[5]  J. Nazir,et al.  Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review , 2018, BMJ Open.

[6]  R. Bödeker,et al.  Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study , 2018, BMC Urology.

[7]  K. Weinfurt,et al.  Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study , 2017, The Journal of urology.

[8]  V. Dandolu,et al.  Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents , 2017, Neurourology and urodynamics.

[9]  Tomomi Kimura,et al.  Persistence and adherence to overactive bladder medications in Japan: A large nationwide real‐world analysis , 2017, International journal of urology : official journal of the Japanese Urological Association.

[10]  H. Bogner,et al.  Is self‐reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder? , 2016, Neurourology and urodynamics.

[11]  K. Weinfurt,et al.  Symptoms of Lower Urinary Tract Dysfunction Research Network. , 2016, The Journal of urology.

[12]  S. Mathew,et al.  Medication Adherence: Truth and Consequences☆ , 2016, The American journal of the medical sciences.

[13]  Tae Heon Kim,et al.  Persistence and compliance with medication management in the treatment of overactive bladder , 2016, Investigative and clinical urology.

[14]  R. Dmochowski,et al.  The Burden of Overactive Bladder on US Public Health , 2016, Current Bladder Dysfunction Reports.

[15]  C. Thompson,et al.  Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS) , 2012, Neurourology and urodynamics.

[16]  K. Giannitsas,et al.  An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder , 2011, Advances in urology.

[17]  Daniel J Buysse,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.

[18]  K. Coyne,et al.  Assessing patients’ descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research , 2010, International journal of clinical practice.

[19]  R. Freeman,et al.  An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, Neurourology and urodynamics.

[20]  T. Kamarck,et al.  A global measure of perceived stress. , 1983, Journal of health and social behavior.